Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Untreated Early-stage or Locally Advanced Breast Cancer

Interventions

DRUG

SHR-A1811

DRUG

Adebrelimab

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06592625 - Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients | Biotech Hunter | Biotech Hunter